CFO4Life Group LLC Takes $235,000 Position in GSK plc (NYSE:GSK)

CFO4Life Group LLC bought a new stake in GSK plc (NYSE:GSK) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,489 shares of the pharmaceutical company’s stock, valued at approximately $235,000.

Several other large investors have also made changes to their positions in GSK. JTC Employer Solutions Trustee Ltd grew its stake in shares of GSK by 71.3% in the 1st quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after buying an additional 8,800,822 shares in the last quarter. Hsbc Holdings PLC bought a new stake in shares of GSK in the 4th quarter valued at approximately $92,281,000. Armistice Capital LLC grew its stake in shares of GSK by 670.5% in the 4th quarter. Armistice Capital LLC now owns 2,196,000 shares of the pharmaceutical company’s stock valued at $81,384,000 after buying an additional 1,911,000 shares in the last quarter. Fisher Asset Management LLC grew its stake in shares of GSK by 10.8% in the 4th quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock valued at $558,330,000 after buying an additional 1,465,165 shares in the last quarter. Finally, Provident Trust Co. grew its stake in shares of GSK by 53.6% in the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock valued at $137,746,000 after buying an additional 1,297,385 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE:GSK traded up $0.32 during midday trading on Friday, reaching $39.22. The company’s stock had a trading volume of 1,634,828 shares, compared to its average volume of 3,577,082. GSK plc has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The company has a market capitalization of $81.28 billion, a P/E ratio of 14.10, a P/E/G ratio of 1.17 and a beta of 0.64. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The business’s fifty day simple moving average is $41.98 and its 200-day simple moving average is $41.29.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.15. The company had revenue of $9.34 billion during the quarter, compared to analyst estimates of $8.98 billion. GSK had a return on equity of 51.54% and a net margin of 14.62%. As a group, equities research analysts expect that GSK plc will post 4.1 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, July 11th. Investors of record on Friday, May 17th were issued a $0.3762 dividend. This is a boost from GSK’s previous quarterly dividend of $0.36. The ex-dividend date was Thursday, May 16th. This represents a $1.50 annualized dividend and a yield of 3.84%. GSK’s dividend payout ratio (DPR) is currently 53.26%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Citigroup raised GSK to a “strong-buy” rating in a research note on Monday, June 24th. Jefferies Financial Group upped their target price on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research report on Monday. The Goldman Sachs Group began coverage on GSK in a research report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price objective for the company. Finally, Berenberg Bank upgraded GSK to a “strong-buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.